From Discovery to Bedside: Targeting the Ubiquitin System

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Drug Discovery

Background:

• The ubiquitin/proteasome system (UPS) is a critical cellular pathway for regulated protein degradation.
• Dysregulation of the UPS is implicated in various diseases, making it a significant target for therapeutic intervention.
• Over 30 years since its discovery, the UPS remains a dynamic research area with approved drugs and ongoing development.

Purpose of the Study:

• To review current and emerging therapeutic strategies targeting the ubiquitin/proteasome system.
• To highlight innovative discoveries and breakthrough therapies in UPS-targeted drug development.
• To provide an overview of compounds in preclinical testing, clinical trials, and those already approved.

Main Methods:

• Literature review of preclinical and clinical studies on UPS-targeting agents.
• Analysis of approved drugs and compounds in various stages of drug development.
• Synthesis of information on novel targets and therapeutic approaches within the UPS.

Main Results:

• Several compounds targeting the UPS are in preclinical and clinical development.
• Approved drugs targeting the UPS demonstrate the therapeutic potential of this pathway.
• Innovative discoveries are continually emerging, expanding the scope of UPS-targeted therapies.

Conclusions:

• The ubiquitin/proteasome system represents a fertile ground for drug discovery and development.
• Targeting the UPS has led to successful therapeutic interventions for various diseases.
• Continued research promises further breakthroughs in UPS-targeted medicine.